Академический Документы
Профессиональный Документы
Культура Документы
Review
Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, First Afliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis, Soochow University,
Ministry of Health, Suzhou, Jiangsu 215123, PR China
Department of Bioinformatics, School of Biology and Basic Medical Sciences, Medical College, Soochow University, Suzhou, Jiangsu 215123, PR China
c
University of Mississippi Cancer Institute, Jackson, MS 39216, USA
d
Department of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
e
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
b
a r t i c l e
i n f o
Article history:
Received 6 January 2013
Received in revised form 6 March 2013
Accepted 11 March 2013
Available online 21 March 2013
Keywords:
Cancer metabolism
Stem cells
Cancer therapy
Oncogenic metabolic genes
a b s t r a c t
Robust anaerobic metabolism plays a causative role in the origin of cancer cells; however, the oncogenic metabolic genes, factors, pathways, and networks in genesis of tumor-initiating cells (TICs) have not yet been systematically summarized. In addition, the mechanisms of oncogenic metabolism in the genesis of TICs are enigmatic.
In this review, we discussed multiple cancer metabolism-related genes (MRGs) that are overexpressed in TICs
and are responsible for inducing pluripotent stem cells. Moreover, we summarized that oncogenic metabolic
genes and onco-metabolites induce metabolic reprogramming, which switches normal mitochondrial oxidative
phosphorylation to cancer anaerobic metabolism, triggers epigenetic, genetic, and environmental alterations,
drives the generation of TICs, and boosts the development of cancer. Importantly, cancer metabolism is controlled by positive and negative metabolic regulators. Positive oncogenic metabolic regulators, including key oncogenic metabolic genes, onco-metabolites, hypoxia, and an acidic environment, promote oncogenic metabolic
reprogramming and anaerobic metabolism. However, dysfunction of negative metabolic regulators, including
defects in p53, PTEN, and LKB1-AMPK-mTOR pathways, enhances cancer metabolism. Loss of the metabolic balance results in oncogenic metabolic reprogramming, genesis of TICs, and tumorigenesis. Collectively, this review
provides new insight into the role and mechanism of these oncogenic metabolisms in the genesis of TICs and tumorigenesis. Accordingly, targeting key oncogenic genes, onco-metabolites, pathways, networks, and the acidic
cancer microenvironment appears to be an attractive strategy for novel anti-tumor treatment.
2013 Elsevier B.V. All rights reserved.
Contents
1.
2.
3.
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overexpression of oncogenic metabolism-related genes triggers the genesis of TICs . .
2.1.
glycine decarboxylase
. . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.
Pyruvate kinase M2
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Metabolic gene mutant driver oncogenic metabolic reprogramming and genesis of TICs
3.1.
Oncogenic reprogramming of glucose metabolism . . . . . . . . . . . . . .
3.1.1.
MYC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.2.
RAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.3.
AKT1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.4.
SRC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.1.5.
BCR-Abl and ALDH2 . . . . . . . . . . . . . . . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
50
50
50
51
51
51
51
51
51
52
52
Correspondence to: Z. Wang, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, USA. Tel.: +1 617
735 2474; fax: +1 617 735 2480.
Correspondence to: Q. Zhou, Cyrus Tang Hematology Center, Soochow University, Room 703-3505, 199 Ren Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, PR China.
Tel.: +86 512 65882116; fax: +86 512 65880929.
E-mail addresses: zwang6@bidmc.harvard.edu (Z. Wang), quanshengzhou@yahoo.com (Q. Zhou).
1
These authors contributed equally to this work.
0304-419X/$ see front matter 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.bbcan.2013.03.001
50
3.2.
Oncogenic metabolic reprogramming of the glutaminolytic pathway . . .
3.3.
Oncogenic metabolic reprogramming of glycine metabolism . . . . . . .
4.
Onco-metabolites cause oncogenic metabolic reprogramming and tumorigenesis
4.1.
2-hydroxyglutarate (2-HG) . . . . . . . . . . . . . . . . . . . . . .
4.2.
Lactate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.3.
Kynurenine (Kyn)
. . . . . . . . . . . . . . . . . . . . . . . . . .
5.
The potential role of non-coding RNA in oncogenic metabolic reprogramming and
5.1.
miRNAs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5.2.
piRNAs and Piwi proteins . . . . . . . . . . . . . . . . . . . . . . .
6.
Loss of the metabolic YinYang balance promotes cancer initiation and progression .
6.1.
Positive oncogenic metabolic regulation . . . . . . . . . . . . . . . .
6.1.1.
Oncogenes and onco-metabolites . . . . . . . . . . . . . . .
6.1.2.
Hypoxia . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.1.3.
Acidic microenvironment . . . . . . . . . . . . . . . . . . .
6.2.
Negative oncogenic metabolic regulation . . . . . . . . . . . . . . . .
6.2.1.
p53 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.2.2.
PTEN . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.2.3.
LKB1 and AMPK . . . . . . . . . . . . . . . . . . . . . . .
7.
Conclusions and perspectives
. . . . . . . . . . . . . . . . . . . . . . . .
Conict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Introduction
In 1927, the biochemist Otto Warburg found that cancer tissues had
a unique metabolic pattern distinct from normal tissues, by which cancer cells preferred a robust anaerobic metabolism even in the presence
of sufcient oxygen [1]. In 1956, Warburg suggested the theory that anaerobic metabolism played a causative role in the origin of cancer cells
[2]. Unfortunately, cancer metabolism had not been paid enough attention for decades until recently when cancer metabolism was recognized
as a hallmark of cancer [3], playing a pivotal role in cell reprogramming
and initiation of cancers [4]. In addition to the rapid progress in cancer
metabolism, another breakthrough in the cancer research eld is the
nding of tumor-initiating cells (TICs) or cancer stem cells (CSCs). In
1997, Bonnet and Dick found that a small subpopulation of CD34+
CD38 leukemic cells displayed strong self-renewal capability and differentiation potential, and could be leukemia-initiating cells [5]. Subsequently, TICs were also found in several solid tumors [6]. More recently,
a pivotal role of TICs in cancer initiation, development, metastasis and
drug resistance has been demonstrated in vivo [7,8]. However, the role
and mechanism of oncogenic metabolism in the genesis of TICs remain
to be further investigated.
Accumulated data have shown that sustained anaerobic metabolism
not only provides energy and various biomaterials to meet the demand
of tumor growth [9,10], but also contributes to the genesis of TICs and
tumorigenesis [3,4,11]. During the initiation and development of malignant tumors, cancer cells usually reprogram their metabolism need
through vigorous aerobic glycolysis to produce sufcient energy and
various biomaterials. For a long time, it was generally believed that
tumor cells underwent robust glycolysis due to a defect in mitochondrial glucose oxidative phosphorylation [1,2]. However, recent studies
have indicated that glucose oxidative phosphorylation in mitochondria
of most cancer cells was normal, and cells preferentially underwent anaerobic metabolism even in the presence of abundant oxygen. Cancer
cells reprogram glucose metabolism, amino acid, lipid, and nucleic
acid metabolism [911]. Cancer metabolism undertakes a complex process that even Warburg did not expect [4,12] and the landscape of cancer metabolism has recently been broadened far beyond the classic
Warburg effect in cancer metabolism.
Despite a tremendous advance in cancer metabolism recently, the
role and mechanism of cancer metabolism in the genesis of TICs and development of cancer remain unclear. In the present article, we extensively discussed recent progress in oncogenic metabolic reprogramming
during the generation of TICs and development of cancers, and addressed
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
tumorigenesis
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
. . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
52
53
53
53
53
53
54
54
54
54
54
54
54
54
55
55
55
56
56
56
56
56
51
resulting in chromosome translocation, gene mutagenesis and generation of oncogenic metabolic genes. Oncogenic metabolic genes induce
reprogramming of glucose, glutamine, and glycine metabolism to
form discrete oncogenic metabolic pathways and networks, driving
the genesis of TICs and development of malignant tumors.
3.1. Oncogenic reprogramming of glucose metabolism
It is well known that cancer cells undergo robust glycolysis to obtain sufcient energy and build biomaterials for their rapid growth.
Overexpression or re-activation of key metabolism-related oncogenes, such as MYC, KRAS, AKT1, SRC, and BCR-ABL, promotes oncogenic reprogramming of glucose metabolism through up-regulation of
several key glycolytic genes, favoring the genesis of TICs and development of cancer (Table 1).
3.1.1. MYC
Overexpression of MYC enhances phosphatidylinositol (PI) metabolism in human kidney cancer cells [29]. MYC up-regulates the expression
of various glucose metabolic genes, including LDHA, PKM2, HK2, PDK1,
C6orf108 (RCL), GLUT1, GPI, phosphofructokinase, GAPDH, phosphoglycerate
kinase, and enolase, and reprograms glucose metabolic pathways [3033].
MYC boosts transcription of PTB, hnRNPA1, and hnRNPA2, enhances the
PKM splicing error, and results in the overexpression of embryonic pyruvate kinase isoform PKM2 that promotes aerobic glycolysis in tumors
[34,35]. In addition, MYC-induced hexokinase 2 (HK2) catalyzes the rst
step of glycolysis, while MYC-induced PDK1 inactivates pyruvate dehydrogenase and diminishes mitochondrial respiration, resulting in a strong
Warburg effect [36]. The glycolysis in hypoxia in cancers also depends on
the cooperation between MYC and HIF1 [36]. Moreover, MYC-induced
overexpression of lactate dehydrogenase A (LDHA) markedly upgrades
glycolysis and leads to overproduction of lactate to form an acidic
tumor microenvironment, which is essential for lactate-driven genesis
of TICs and MYC-mediated oncogenic transformation and tumorigenesis [37,38]. MYC also reprograms glutamine, proline, glycine, and lipid
metabolic pathways, as well as elevates the expression of genes that
are related to fatty acid and glycerophospholipid synthesis, such as
MECR, ACSL1, AACS, ACAT1, AGAPT5, DGAT2, and LYPLA1, resulting in an
increase in lipid biosynthesis [39]. Additionally, MYC regulates the ketogenic metabolism pathway through down-regulation of HMGCS2 gene
expression [40,41]. Furthermore, MYC promotes the nucleotide biosynthetic pathway via up-regulation of TYMS, IMPDH1, IMPDH2, and PRPS2
in various tumors [4244], as well as inhibits p53 function, thereby advancing tumorigenesis [45]. Consistent with the pivotal role of MYC in
oncogenic metabolic reprogramming, our recent bioinformatic analysis
indicated that MYC was overexpressed in various human cancer stem
cells and malignant tumor tissues [13]. Together, MYC could be a master
oncogenic metabolic driver for metabolic reprogramming, genesis of
TICs, and tumorigenesis.
3.1.2. RAS
Overexpression of RAS family oncogenes (KRAS, HRAS, and NRAS) induces oncogenic metabolic reprogramming, stimulates glycolysis to produce lactate and alpha-ketoglutarate (-KG), and enhances synthesis of
nucleic acids and lipids [4648]. Activation of KRAS (G12V) decreases
mitochondrial glucose oxidative phosphorylation, but increases glycolysis in cells [49]. Additionally, RAS stimulates phospholipid metabolism
via up-regulation of either phospholipase C or phospholipase A2 activity
in the inositol phospholipid signaling pathway [5052]. Thus, RASmediated oncogenic metabolic reprogramming, including glycolysis
and lipid metabolism, is vital to support cancer cell growth [53].
3.1.3. AKT1
Frequent dysregulation of AKT1 has been observed in various human
cancers. AKT1, a serine/threonine kinase, has been found to promote cell
survival and suppress apoptosis through multiple mechanisms including
52
Table 1
Oncogenic metabolic reprogramming drives the genesis of tumor-initiating cells and tumorigenesis.
Gene name
Reference
MYC
[2945,6466]
[54]
AKT1
SRC
BCR-ABL
CD44
GLDC
PTP4A1, PTP4A2
ALDH2
2-Hydroxyglutarate (2-HG)
IDH1, IDH2
Lactate
Kynurenine (Kyn)
[4653]
[55,56]
[57,60]
[18]
[11,71]
[7388]
[26,27]
[28]
[7388]
[8991]
[9396]
the regulation of glucose metabolism. AKT1 can increase mitochondriaassociated hexokinase (hexokinase I and II) activity and inhibit
cytochrome c release and apoptosis in cancer cells. Similar to MYC,
the activation of AKT1 can also lead to the Warburg effect through increased cellular glucose uptake, glycolysis, and lactate generation.
Once inhibiting glycolysis, AKT1-activated cells are susceptible to apoptosis which is different from MYC-activated cells that are sensitive to
the inhibition of mitochondrial function [54]. Therefore, it is required
to further investigate the molecular mechanism of AKT1-regulated cancer metabolism.
3.1.4. SRC
The tyrosine kinase SRC is overexpressed in several cancer cells, and
differentiated cells rely mainly on oxidative phosphorylation to generate ATP. It has been demonstrated that the activation of SRC regulates
phosphoinositide metabolism through stimulating the expression of
basal phospholipase A2 (PLA2), and induces the remodeling of energetic metabolism through the stabilization of HIF1A and increased activities of several glycolytic enzymes including HK1 and HK2 [55]. The
activation of SRC can promote the metabolic reprogramming and subsequently elevate aerobic glycolysis in cancer cells. Moreover, SRC kinase
sustains mitochondrial respiration by phosphorylating the NDUFB10
subunit of complex I in human cancer cells [56]. Without a doubt, the
exact molecular mechanism by which SRC promotes reprogramming
of glucose metabolism needs to be further elucidated.
The other oncogenic metabolic reprogramming involves glutaminolysis. When tumor cells undergo robust glycolysis, glucose cannot
effectively enter the tricarboxylic acid (TCA) cycle to produce sufcient adenosine-5-triphosphate (ATP) and biomaterials required for
rapid tumor growth; alternatively, tumor cells manage to reprogram
glutaminolytic and biosynthetic pathways. Increased glutaminolysis
is now recognized as a key feature of the cancer metabolism and
contributes to the core metabolism of proliferating cells by supporting
energy production and biosynthesis [62]. Oncogenic MYC plays a pivotal
role in metabolic reprogramming of the glutaminolytic pathway. MYC
stimulates mitochondrial glutamine uptake and catabolism to meet the
cellular requirement for protein and nucleotide biosynthesis through
up-regulation of glutaminolytic genes, such as genes encoding the glutamine importers ASCT2 and SN2 [63]. MYC also enhances the expression of
mitochondrial glutaminase, which stimulates glutamine metabolism and
converts glutamine to glutamate, as well as increases mitochondrial production of acetyl-CoA for fatty acid biosynthesis [6466]. In addition, MYC
also promotes proline anabolism by inhibiting proline oxidase and enhancing the enzyme activity of proline biosynthesis from glutamine
[64]. Obviously, tumor cells reprogram the metabolic pathway to obtain
53
4.2. Lactate
Traditionally, lactate from glycolysis has been considered a highenergy metabolic fuel for tumor cells. Emerging evidence has shown
that lactate in tumor tissues also plays a pivotal role in metabolic
reprogramming, which is an early event in the development of malignant
tumors; additionally, high lactate levels in cancer patients have been
identied as a prognostic parameter for metastasis and poor overall survival of cancer patients [89]. Ubaldo et al. recently reported that lactate
not only promoted stem cell growth, but also increased cell stemness.
Mechanistic studies revealed that lactate caused cell reprogramming
through overexpression of genes associated with stemness, including
genes that encode several stem cell-associated transcription factors
(SP1, MAZ, MEIS1, MLLT7, LEF1, TCF3, ELK1, SREBF1, PAX4, and ESRRA); additionally, lactate elevated nuclear histone acetylation and epigenetic alteration in MCF7 cancer cells and promoted dissociation of histones
from DNA, as well as enhanced gene transcription [89]. Lactate also promotes the production and secretion of VEGF, a potent tumor angiogenic
driver, and induces the formation of tumor new vasculature and growth
[90]. In addition to tumor cell production of lactate, cancer-associated broblasts undergo strong aerobic glycolysis and secrete lactate to feed
adjacent cancer cells, promoting cell reprogramming and increasing cell
stemness [91]. In addition, lactate recruits human MSCs towards
tumor cells to enhance stem cell migration [92]. Furthermore, L-lactate
stimulates cancer metastasis in the lung by 10-fold [92]. Collectively, the
onco-metabolite lactate causes oncogenic metabolic reprogramming
and enhances cell stemness, genesis of TICs, and tumor growth; and accumulation of lactate in solid tumors is an important early event in the development of cancer.
54
55
Fig. 1. Loss of metabolic YinYang balance causes the initiation of TICs and development of malignant tumors. An increase in key oncogenic metabolic drivers and decrease in oncogenic metabolic inhibitors result in loss of the balance of metabolic-regulation and cause metabolic reprogramming, genesis of TICs, and tumorigenesis. Legends:
activation,
inactivation.
6.2.2. PTEN
The tumor suppressor gene PTEN encodes a lipid phosphatase that
degrades phosphatidylinositol-3,4,5-triphosphate and inhibits the
PI3K-Akt-mTOR pathway. PTEN governs cellular energy metabolism
and many other activities [130]. PTEN transgenic mice show increased
energy expenditure and reduced body fat accumulation. Cells derived
from these mice show reduced glycolysis and glucose but increased mitochondrial oxidative phosphorylation, and the cells are resistant to oncogenic transformation. Elevation of the PTEN level and activity inhibits
PI3K-Akt-mTOR-dependent and -independent pathways and reverses
cancer metabolism from glycolysis to oxidative phosphorylation. Thus,
PTEN acts as an inhibitor of oncogenic metabolism [131,132]. PTEN
loss leads to the activation of the PI3K/AKT signaling pathway and
switch to cancer metabolism, which correlates with human cancer initiation, progression, and metastasis [133]. In addition, PTEN loss in prostate cancer causes signicant enhancement in the RAS/MAPK pathway
and increases stem/progenitor subpopulation, causing epithelial-tomesenchymal transition (EMT) and macrometastasis [134]. Together,
PTEN is an important negative oncogenic metabolic regulator.
56
57
[37] B.C. Lewis, J.E. Prescott, S.E. Campbell, H. Shim, R.Z. Orlowski, C.V. Dang, Tumor
induction by the c-Myc target genes rcl and lactate dehydrogenase A, Cancer
Res. 60 (2000) 61786183.
[38] H. Shim, Y.S. Chun, B.C. Lewis, C.V. Dang, A unique glucose-dependent apoptotic
pathway induced by c-Myc, Proc. Natl. Acad. Sci. U S A. 95 (1998) 15111516.
[39] F. Morrish, N. Isern, M. Sadilek, M. Jeffrey, D.M. Hockenbery, c-Myc activates
multiple metabolic networks to generate substrates for cell-cycle entry, Oncogene 28 (2009) 24852491.
[40] N. Camarero, C. Mascaro, C. Mayordomo, F. Vilardell, D. Haro, P.F. Marrero, Ketogenic
HMGCS2 Is a c-Myc target gene expressed in differentiated cells of human colonic epithelium and down-regulated in colon cancer, Mol. Cancer Res. 4 (2006) 645653.
[41] N.T. Telang, F. Arcuri, O.M. Granata, H.L. Bradlow, M.P. Osborne, L. Castagnetta,
Alteration of oestradiol metabolism in myc oncogene-transfected mouse mammary epithelial cells, Br. J. Cancer 77 (1998) 15491554.
[42] C.V. Dang, A. Le, P. Gao, MYC-induced cancer cell energy metabolism and therapeutic opportunities, Clin. Cancer Res. 15 (2009) 64796483.
[43] Y.C. Liu, F. Li, J. Handler, C.R. Huang, Y. Xiang, N. Neretti, J.M. Sedivy, K.I. Zeller,
C.V. Dang, Global regulation of nucleotide biosynthetic genes by c-Myc, PLoS
One 3 (2008) e2722.
[44] S. Mannava, V. Grachtchouk, L.J. Wheeler, M. Im, D. Zhuang, E.G. Slavina, C.K.
Mathews, D.S. Shewach, M.A. Nikiforov, Direct role of nucleotide metabolism in
C-MYC-dependent proliferation of melanoma cells, Cell Cycle 7 (2008) 23922400.
[45] O. Vafa, M. Wade, S. Kern, M. Beeche, T.K. Pandita, G.M. Hampton, G.M. Wahl,
c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate
p53 function: a mechanism for oncogene-induced genetic instability, Mol. Cell
9 (2002) 10311044.
[46] S. Telang, A. Yalcin, A.L. Clem, R. Bucala, A.N. Lane, J.W. Eaton, J. Chesney, Ras
transformation requires metabolic control by 6-phosphofructo-2-kinase, Oncogene 25 (2006) 72257234.
[47] F. Weinberg, R. Hamanaka, W.W. Wheaton, S. Weinberg, J. Joseph, M. Lopez, B.
Kalyanaraman, G.M. Mutlu, G.R. Budinger, N.S. Chandel, Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity, Proc.
Natl. Acad. Sci. U. S. A. 107 (2010) 87888793.
[48] P. Vizan, L.G. Boros, A. Figueras, G. Capella, R. Mangues, S. Bassilian, S. Lim, W.N. Lee,
M. Cascante, K-ras codon-specic mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] broblasts, Cancer Res. 65 (2005) 55125515.
[49] Y. Hu, W. Lu, G. Chen, P. Wang, Z. Chen, Y. Zhou, M. Ogasawara, D. Trachootham, L.
Feng, H. Pelicano, P.J. Chiao, M.J. Keating, G. Garcia-Manero, P. Huang, K-ras(G12V)
transformation leads to mitochondrial dysfunction and a metabolic switch from
oxidative phosphorylation to glycolysis, Cell Res. 22 (2012) 399412.
[50] M. Huang, K. Chida, N. Kamata, K. Nose, M. Kato, Y. Homma, T. Takenawa, T. Kuroki,
Enhancement of inositol phospholipid metabolism and activation of protein kinase
C in ras-transformed rat broblasts, J. Biol. Chem. 263 (1988) 1797517980.
[51] T. Alonso, R.O. Morgan, J.C. Marvizon, H. Zarbl, E. Santos, Malignant transformation by ras and other oncogenes produces common alterations in inositol phospholipid signaling pathways, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 42714275.
[52] C.L. Yu, M.H. Tsai, D.W. Stacey, Cellular ras activity and phospholipid metabolism, Cell 52 (1988) 6371.
[53] D. Gaglio, C.M. Metallo, P.A. Gameiro, K. Hiller, L.S. Danna, C. Balestrieri, L. Alberghina,
G. Stephanopoulos, F. Chiaradonna, Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth, Mol. Syst. Biol. 7 (2011) 523.
[54] Y. Fan, K.G. Dickman, W.X. Zong, Akt and c-Myc differentially activate cellular
metabolic programs and prime cells to bioenergetic inhibition, J. Biol. Chem.
285 (2010) 73247333.
[55] R. Karni, Y. Dor, E. Keshet, O. Meyuhas, A. Levitzki, Activated pp 60c-Src leads to
elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia, J. Biol.
Chem. 277 (2002) 4291942925.
[56] E. Hebert-Chatelain, C. Jose, C.N. Gutierrez, J.W. Dupuy, C. Rocher, J. Dachary-Prigent, T.
Letellier, Preservation of NADH ubiquinone-oxidoreductase activity by Src kinasemediated phosphorylation of NDUFB10, Biochim. Biophys. Acta 1817 (2012)
718725.
[57] C.G. Geary, The story of chronic myeloid leukaemia, Br. J. Haematol. 110 (2000)
211.
[58] P. Tandon, C.A. Gallo, S. Khatri, J.F. Barger, H. Yepiskoposyan, D.R. Plas, Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deciency, Proc. Natl. Acad. Sci. U. S. A. 108 (2011)
23612365.
[59] K. Duvel, J.L. Yecies, S. Menon, P. Raman, A.I. Lipovsky, A.L. Souza, E. Triantafellow, Q.
Ma, R. Gorski, S. Cleaver, H.M. Vander, J.P. MacKeigan, P.M. Finan, C.B. Clish, L.O.
Murphy, B.D. Manning, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol. Cell 39 (2010) 171183.
[60] J.F. Barger, C.A. Gallo, P. Tandon, H. Liu, A. Sullivan, H.L. Grimes, D.R. Plas, S6K1
determines the metabolic requirements for BCR-ABL survival, Oncogene 32
(2013) 453461.
[61] F. Langevin, G.P. Crossan, I.V. Rosado, M.J. Arends, K.J. Patel, Fancd2 counteracts the
toxic effects of naturally produced aldehydes in mice, Nature 475 (2011) 5358.
[62] D. Daye, K.E. Wellen, Metabolic reprogramming in cancer: unraveling the role of
glutamine in tumorigenesis, Semin. Cell Dev. Biol. 23 (2012) 362369.
[63] D.R. Wise, R.J. DeBerardinis, A. Mancuso, N. Sayed, X.Y. Zhang, H.K. Pfeiffer, I.
Nissim, E. Daikhin, M. Yudkoff, S.B. McMahon, C.B. Thompson, Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1878218787.
[64] W. Liu, A. Le, C. Hancock, A.N. Lane, C.V. Dang, T.W. Fan, J.M. Phang, Reprogramming
of proline and glutamine metabolism contributes to the proliferative and metabolic
responses regulated by oncogenic transcription factor c-MYC, Proc. Natl. Acad. Sci.
U. S. A. 109 (2012) 89838988.
58
[87] M. Sasaki, C.B. Knobbe, J.C. Munger, E.F. Lind, D. Brenner, A. Brustle, I.S. Harris, R.
Holmes, A. Wakeham, J. Haight, A. You-Ten, W.Y. Li, S. Schalm, S.M. Su, C.
Virtanen, G. Reifenberger, P.S. Ohashi, D.L. Barber, M.E. Figueroa, A. Melnick,
J.C. Zuniga-Pucker, T.W. Mak, IDH1(R132H) mutation increases murine
haematopoietic progenitors and alters epigenetics, Nature 488 (2012) 656659.
[88] P. Koivunen, S. Lee, C.G. Duncan, G. Lopez, G. Lu, S. Ramkissoon, J.A. Losman, P. Joensuu,
U. Bergmann, S. Gross, J. Travins, S. Weiss, R. Looper, K.L. Ligon, R.G. Verhaak, H. Yan,
W.J. Kaelin, Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to
EGLN activation, Nature 483 (2012) 484488.
[89] U.E. Martinez-Outschoorn, M. Prisco, A. Ertel, A. Tsirigos, Z. Lin, S. Pavlides, C.
Wang, N. Flomenberg, E.S. Knudsen, A. Howell, R.G. Pestell, F. Sotgia, M.P.
Lisanti, Ketones and lactate increase cancer cell stemness, driving recurrence,
metastasis and poor clinical outcome in breast cancer: achieving personalized
medicine via Metabolo-Genomics, Cell Cycle 10 (2011) 12711286.
[90] F. Hirschhaeuser, U.G. Sattler, W. Mueller-Klieser, Lactate: a metabolic key player in cancer, Cancer Res. 71 (2011) 69216925.
[91] D. Whitaker-Menezes, U.E. Martinez-Outschoorn, Z. Lin, A. Ertel, N. Flomenberg,
A.K. Witkiewicz, R.C. Birbe, A. Howell, S. Pavlides, R. Gandara, R.G. Pestell, F.
Sotgia, N.J. Philp, M.P. Lisanti, Evidence for a stromal-epithelial lactate shuttle
in human tumors: MCT4 is a marker of oxidative stress in cancer-associated broblasts, Cell Cycle 10 (2011) 17721783.
[92] Y.I. Rattigan, B.B. Patel, E. Ackerstaff, G. Sukenick, J.A. Koutcher, J.W. Glod, D.
Banerjee, Lactate is a mediator of metabolic cooperation between stromal carcinoma associated broblasts and glycolytic tumor cells in the tumor microenvironment, Exp. Cell Res. 318 (2012) 326335.
[93] C.A. Opitz, U.M. Litzenburger, F. Sahm, M. Ott, I. Tritschler, S. Trump, T. Schumacher, L.
Jestaedt, D. Schrenk, M. Weller, M. Jugold, G.J. Guillemin, C.L. Miller, C. Lutz, B.
Radlwimmer, I. Lehmann, A. von Deimling, W. Wick, M. Platten, An endogenous
tumour-promoting ligand of the human aryl hydrocarbon receptor, Nature 478
(2011) 197203.
[94] G.C. Prendergast, Cancer: why tumours eat tryptophan, Nature 478 (2011) 192194.
[95] R.A. de Jong, H.W. Nijman, H.M. Boezen, M. Volmer, H.K. Ten, J. Krijnen, A.G. van der
Zee, H. Hollema, I.P. Kema, Serum tryptophan and kynurenine concentrations as
parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial,
ovarian, and vulvar cancer, Int. J. Gynecol. Cancer 21 (2011) 13201327.
[96] D.E. Lyon, J.M. Walter, A.R. Starkweather, C.M. Schubert, N.L. McCain, Tryptophan
degradation in women with breast cancer: a pilot study, BMC Res. Notes 4
(2011) 156.
[97] P.K. Singh, R.E. Brand, K. Mehla, MicroRNAs in pancreatic cancer metabolism,
Nat. Rev. Gastroenterol. Hepatol. 9 (2012) 334344.
[98] I.K. Guttilla, B.A. White, Coordinate regulation of FOXO1 by miR-27a, miR-96,
and miR-182 in breast cancer cells, J. Biol. Chem. 284 (2009) 2320423216.
[99] P.P. Medina, M. Nolde, F.J. Slack, OncomiR addiction in an in vivo model of
microRNA-21-induced pre-B-cell lymphoma, Nature 467 (2010) 8690.
[100] Y. Yu, S.S. Kanwar, B.B. Patel, P.S. Oh, J. Nautiyal, F.H. Sarkar, A.P. Majumdar,
MicroRNA-21 induces stemness by downregulating transforming growth factor
beta receptor 2 (TGFbetaR2) in colon cancer cells, Carcinogenesis 33 (2012) 6876.
[101] N. Koide, K. Yasuda, K. Kadomatsu, Y. Takei, Establishment and optimal culture conditions of microrna-induced pluripotent stem cells generated from HEK293 cells via
transfection of microrna-302 s expression vector, Nagoya J. Med. Sci. 74 (2012)
157165.
[102] D.R. Boutz, P.J. Collins, U. Suresh, M. Lu, C.M. Ramirez, C. Fernandez-Hernando, Y.
Huang, R.S. Abreu, Le SY, B.A. Shapiro, A.M. Liu, J.M. Luk, S.F. Aldred, N.D.
Trinklein, E.M. Marcotte, L.O. Penalva, Two-tiered approach identies a network
of cancer and liver disease-related genes regulated by miR-122, J. Biol. Chem.
286 (2011) 1806618078.
[103] J. Burchard, C. Zhang, A.M. Liu, R.T. Poon, N.P. Lee, K.F. Wong, P.C. Sham, B.Y. Lam,
M.D. Ferguson, G. Tokiwa, R. Smith, B. Leeson, R. Beard, J.R. Lamb, L. Lim, M. Mao,
H. Dai, J.M. Luk, microRNA-122 as a regulator of mitochondrial metabolic gene
network in hepatocellular carcinoma, Mol. Syst. Biol. 6 (2010) 402.
[104] A. Peschiaroli, A. Giacobbe, A. Formosa, E.K. Markert, L. Bongiorno-Borbone, A.J.
Levine, E. Candi, A. D'Alessandro, L. Zolla, A.A. Finazzi, G. Melino, miR-143 regulates hexokinase 2 expression in cancer cells, Oncogene 32 (2013) 797802.
[105] H. Zhai, B. Song, X. Xu, W. Zhu, J. Ju, Inhibition of autophagy and tumor growth in
colon cancer by miR-502, Oncogene 32 (2013) 15701579.
[106] C. Zou, Q. Xu, F. Mao, D. Li, C. Bian, L.Z. Liu, Y. Jiang, X. Chen, Y. Qi, X. Zhang, X.
Wang, Q. Sun, H.F. Kung, M.C. Lin, A. Dress, F. Wardle, B.H. Jiang, L. Lai,
MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF, Cell
Cycle 11 (2012) 21372145.
[107] H.R. Kim, J.S. Roe, J.E. Lee, I.Y. Hwang, E.J. Cho, H.D. Youn, A p53-inducible
microRNA-34a downregulates Ras signaling by targeting IMPDH, Biochem.
Biophys. Res. Commun. 418 (2012) 682688.
[108] X. Yang, X. Lin, X. Zhong, S. Kaur, N. Li, S. Liang, H. Lassus, L. Wang, D. Katsaros, K.
Montone, X. Zhao, Y. Zhang, R. Butzow, G. Coukos, L. Zhang, Double-negative feedback
loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde
dehydrogenase 1-positive cancer stem cells, Cancer Res. 70 (2010) 94639472.
[109] B. Kefas, L. Comeau, N. Erdle, E. Montgomery, S. Amos, B. Purow, Pyruvate kinase
M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells, Neuro Oncol. 12 (2010) 11021112.
[110] V. Aumiller, K. Frstemann, Roles of microRNAs beyond developmentmetabolism and neural plasticity, Biochim. Biophys. Acta. 1779 (2008) 692696.
[111] M. Mutallip, N. Nohata, T. Hanazawa, N. Kikkawa, S. Horiguchi, L. Fujimura, K.
Kawakami, T. Chiyomaru, H. Enokida, M. Nakagawa, Y. Okamoto, N. Seki, Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by
miR-133alpha in head and neck squamous cell carcinoma (HNSCC), Int. J. Mol.
Med. 27 (2011) 345352.
[141]
[142]
[143]
[144]
[145]
[146]
[147]
[148]
[149]
[150]
[151]
[152]
[153]
[154]
[155]
[156]
[157]
[158]
[159]
[160]
[161]
[162]
[163]
[164]
[165]
[166]
[167]
[168]
[169]
[170]
59